neoplasms

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

BACKGROUND

Cancer cachexia is a serious condition during the last stages of the disease, which is characterized by the loss of muscle and fat mass in patients with cancer. There are no effective treatments for cancer cachexia, and new treatment interventions...

🗓️ 2026-06-25
Read MoreCombination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

An immunological panacea for cancer-related cachexia.

Cancer cachexia, responsible for up to 30% of cancer deaths, has transitioned conceptually from a mere nutritional deficit into a highly coordinated, multi-organ immunometabolic network that systematically dismantles host homeostasis. This review synthesizes the paradigm-shifting discoveries that position the immune...

🗓️ 2026-06-25
📰 Publication: Trends In Cancer
Read MoreAn immunological panacea for cancer-related cachexia.

Autophagy in cancer cachexia: From mechanisms to therapeutic opportunities.

Cancer cachexia is a multifactorial syndrome characterized by body weight loss, muscle wasting, and systemic metabolic alterations, significantly contributing to patient morbidity and mortality. A key feature of cachexia is the excessive degradation of muscle proteins and mitochondria, largely mediated...

🗓️ 2026-06-11
Read MoreAutophagy in cancer cachexia: From mechanisms to therapeutic opportunities.

MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

BACKGROUND

Cancer cachexia is a multifactorial metabolic syndrome marked by progressive skeletal muscle loss, reduced function, and increased mortality. Mitochondrial dysfunction is a key driver of this phenotype. MOTS-c, a mitochondrial-derived peptide that regulates metabolic homeostasis and mimics exercise signaling, may...

🗓️ 2026-06-10
Read MoreMOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

Lowered Abundance of Gut Bacteriophage Species Is Associated With Human Cancer Cachexia.

BACKGROUND

Cancer cachexia exemplifies a high medical need condition without effective treatment. Recent studies implicated bacterial gut microbiome alterations to cancer cachexia. Whether the gut bacteriophage profile, an important microbiome component for health and disease, is also related to cancer cachexia...

🗓️ 2026-06-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLowered Abundance of Gut Bacteriophage Species Is Associated With Human Cancer Cachexia.

PEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Cancer-associated cachexia (CAC) is a multifactorial metabolic syndrome characterized by progressive skeletal muscle wasting. However, the molecular link between tumor metabolic stress and muscle degradation remains elusive. Here, we identify phosphatidylethanolamine-binding protein 4 (PEBP4) as a key regulator of muscle...

🗓️ 2026-06-04
📰 Publication: Cell Death & Disease
Read MorePEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Exercise training prior to and during cancer in mice preserves muscle mass, reduces tumour weight and suppresses molecular mediators of cachexia.

We investigated the prophylactic effects of exercise before and during cancer cachexia (CC) using a model designed to mimic endurance and resistance (i.e., concurrent) adaptations. Male and female Balb/c mice were randomly assigned to exercise or control groups whereby exercise...

🗓️ 2026-06-04
📰 Publication: Journal Of Physiology-London
Read MoreExercise training prior to and during cancer in mice preserves muscle mass, reduces tumour weight and suppresses molecular mediators of cachexia.

Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.

PURPOSE

The adverse prognostic impact of cancer cachexia is well recognized. We aimed to evaluate the prognostic impact of weight loss during first-line platinum-based chemo(immuno)therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC).

METHODS

We retrospectively reviewed 187 of 346 ED-SCLC patients (54%)...

🗓️ 2026-06-02
📰 Publication: Supportive Care In Cancer
Read MorePrognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.

Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

BACKGROUND

Cancer cachexia is a debilitating syndrome marked by involuntary weight loss resulting from reduced food intake and intricate metabolic reprogramming. Despite its high prevalence, cancer cachexia remains undertreated, with a lack of effective and approved pharmacotherapies. Ghrelin has emerged as...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNovel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

Glial remodeling and neuroprotective effects of L-glutamine supplementation on the enteric nervous system in walker-256 tumor-bearing rats.

Cancer cachexia is characterized by systemic inflammation and severe metabolic imbalance, which may compromise the cellular components of the enteric nervous system (ENS). Oxidative stress associated with tumor growth can contribute to enteric neuropathy and gastrointestinal dysfunction. This study investigated...

🗓️ 2026-05-31
📰 Publication: Tissue & Cell
Read MoreGlial remodeling and neuroprotective effects of L-glutamine supplementation on the enteric nervous system in walker-256 tumor-bearing rats.

Eating-related distress in cancer cachexia: multicentre self-reported questionnaire study.

OBJECTIVES

The Asian Working Group for Cachexia (AWGC) updated the diagnostic criteria for cachexia, emphasising its multidimensional influence. We hypothesised that patients meeting the AWGC criteria would exhibit higher levels of eating-related distress (ERD) than those meeting the European Palliative Care...

🗓️ 2026-05-28
📰 Publication: Bmj Supportive & Palliative Care
Read MoreEating-related distress in cancer cachexia: multicentre self-reported questionnaire study.

Formation of Liver Metastases Is Accompanied by Accelerated Musculoskeletal Deficits in LLC Tumor Hosts.

Lung cancer is a leading cause of death worldwide and is often accompanied by declines in musculoskeletal health (i.e., cachexia). Despite affecting a majority of lung cancer patients, cachexia remains understudied and currently has no cure. We have previously demonstrated...

🗓️ 2026-05-27
📰 Publication: International Journal Of Molecular Sciences
Read MoreFormation of Liver Metastases Is Accompanied by Accelerated Musculoskeletal Deficits in LLC Tumor Hosts.

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

BACKGROUND

Cancer cachexia is associated with rapid body wasting and cardiac dysfunction. Bisoprolol (BIS) and megestrol acetate (MA) improve selected cachexia phenotypes in the Yoshida AH-130 model, but their combined effects are not defined. We tested reduced-dose combined treatment of BIS...

🗓️ 2026-05-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCombined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Liver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Cancer cachexia, characterized by weight loss, muscle wasting, and anorexia, complicates cancer treatment and adversely affects patient outcomes. Both tumor-derived and host inflammatory factors are implicated in aspects of cachexia. The search for circulating mediators of cancer cachexia has focused...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreLiver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Cachexia is a metabolic wasting syndrome affecting many patients with cancer, with poor survival outcomes. Disturbed lipid metabolism is a hallmark of cachexia, and our previous work has identified increased levels of circulating ceramides, which are bioactive lipids with adverse...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreInhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!